# IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)

> **NCT00351949** · PHASE1 · COMPLETED · sponsor: **Immutep S.A.S.** · enrollment: 24 (actual)

## Conditions studied

- Stage IV Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** IMP321

## Key facts

- **NCT ID:** NCT00351949
- **Lead sponsor:** Immutep S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-08
- **Final completion:** 2008-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2010-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00351949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00351949, "IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00351949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*